Towa Pharmaceutical Expands and Revises Earnings Forecast
Company Announcements

Towa Pharmaceutical Expands and Revises Earnings Forecast

Towa Pharmaceutical Co (JP:4553) has released an update.

Towa Pharmaceutical Co. has released a supplementary material for their Q1 financial results, detailing the inclusion of new subsidiaries in their consolidated balance sheets and statements of income for the fiscal year ending March 31, 2025. The report specifies that KAMATA and Kyushu Iyaku became consolidated subsidiaries in early 2024, while Sun Freres Lab was established in April 2024. Additionally, the company has revised its full-year earnings forecast.

For further insights into JP:4553 stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Japan Auto-Generated NewsdeskTowa Pharmaceutical Reports Strong Q1 2024 Growth
TipRanks Japan Auto-Generated NewsdeskTowa Pharmaceutical Raises Profit Forecasts
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App